GlassScriptPhysician profile
Avishai Mendelson
NPI 1760476477
$6,546.97
in general payments reported to CMS, 2019-2025
36 companies · $748 in 2025
The $748 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,558 · 2020: $431 · 2021: $1,354 · 2022: $1,395 · 2023: $741 · 2024: $321 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,398.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $811.42 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $591.39 | 2019-2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $435.31 | 2021-2023 | |
| Abbvie INC. | $368.96 | 2021-2025 | |
| Lilly USA, LLC | $349.43 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $287.83 | 2019-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $247.43 | 2021-2025 | |
| Nevro Corp. | $245.40 | 2020-2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.68 | 2019-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.43 | 2019-2022 | |
| Amarin Pharma, INC. | $136.97 | 2019 | |
| Relievant Medsystems, INC. | $135.88 | 2022 | |
| Cleerly, INC. | $125.56 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Antares Pharma, INC. | $125.30 | 2022-2025 | Xyosted |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $92.26 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Allergan, INC. | $82.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $77.77 | 2019-2020 | |
| Exact Sciences Corporation | $64.62 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $60.81 | 2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $60.15 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $57.71 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $56.19 | 2023 | Fanapt, Hetlioz |
| Shield Therapeutics INC | $55.25 | 2025 | |
| Boston Scientific Corporation | $50.51 | 2019-2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $41.96 | 2019-2022 | |
| Astellas Pharma US INC | $36.30 | 2019 | |
| Seqirus USA INC | $27.66 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Biohaven Pharmaceutical Holding Company LTD. | $24.27 | 2022 | |
| Abbott Laboratories | $23.81 | 2024 | Freestyle Libre 3 |
| Pacira Therapeutics, INC. | $20.54 | 2019 | |
| Organogenesis INC. | $17.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.59 | 2019 | |
| Vertiflex, INC. | $12.80 | 2019 | |
| Radius Health, INC. | $12.32 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avishai Mendelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.